Oramed Pharmaceuticals ORMP Institutional Ownership

Ownership Summary

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has 64 institutional investors that have filed 13F reports for the period ending March 2026.

• They owned 32.5% of outstanding stock in March 2026, up from 32.2% the prior quarter.
• They increased total shares held in Oramed Pharmaceuticals by 18.4% from the prior quarter, while the number of investors in ORMP increased 20.75% year over year.
• During the quarter, 36 of these 64 funds increased positions in ORMP, 16 reduced exposure, and 12 held steady.
• The aggregate institutional position in Oramed Pharmaceuticals amounted to 13.24Mn shares as of March 2026, up by 2.06Mn shares quarter on quarter, and up 5.25Mn shares year over year.
• As of March 31, 2026, BML Capital Management, LLC held the largest stake in Oramed Pharmaceuticals with 3.17Mn shares, accounting for 7.77% of total shares outstanding.
• Top purchasers of ORMP stock for the quarter ending March 2026 included MERCER GLOBAL ADVISORS INC /ADV (1.91Mn), RITHOLTZ WEALTH MANAGEMENT (155.48K), Aquamarine Financial (Cayman) Ltd (139.26K), O'SHAUGHNESSY ASSET MANAGEMENT, LLC (116.36K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (110.23K).
• Leading sellers of Oramed Pharmaceuticals shares for the quarter ending March 2026 were Gem Investment Advisors, LLC (358.73K), Rathbones Group PLC (233.02K), CITADEL ADVISORS LLC (97.39K), JANE STREET GROUP, LLC (25.72K), Murchinson Ltd. (24.95K).
• Per Business Quant, the top 10 investors in ORMP for the quarter ending March 2026 include BML Capital Management, LLC (3.17Mn), Aquamarine Financial (Cayman) Ltd (2.11Mn), MERCER GLOBAL ADVISORS INC /ADV (1.91Mn), Gem Investment Advisors, LLC (1.64Mn), Murchinson Ltd. (1.32Mn), BOOTHBAY FUND MANAGEMENT, LLC (600.72K), MARSHALL WACE, LLP (259.61K), Rathbones Group PLC (233.02K), DIMENSIONAL FUND ADVISORS LP (158.21K), Wells Fargo & Company/Mn (157.59K).